Lobbying disclosure profile
Clinical stage biotechnology company
This profile groups public LDA.gov disclosure records connected through shared filings, clients, registrants, lobbyists, issue areas, and bill references. It is source-attributed research context only, not proof of influence, causation, endorsement, lobbying effectiveness, or legislative intent.
Issues related to rare pediatric disease Priority Review Vouchers; H.R. 1262/S. 932, Give Kids a Chance Act; S. 3302, Mikaela Naylon Give Kids a Chance Act of 2025.
Open LDA filing sourceIssues related to rare pediatric disease Priority Review Vouchers; H.R. 1262/S. 932, Give Kids a Chance Act; S. 3302, Mikaela Naylon Give Kids a Chance Act of 2025.
Open LDA filing sourceIssues related to rare pediatric disease Priority Review Vouchers; H.R. 1262/S. 932, Give Kids a Chance Act; S. 3302, Mikaela Naylon Give Kids a Chance Act of 2025.
Open LDA filing source